Comparison of Intensity Modulated Proton Therapy Beam Configurations for Treating Thoracic Esophageal Cancer

Overview

Journal Phys Imaging Radiat Oncol

Specialty Oncology

Date 2022 May 6

PMID 35514527

Authors

Sornjarod Oonsiri

Sarin Kitpanit

Danita Kannarunimit

Chakkapong Chakkabat

Chawalit Lertbutsayanukul

Anussara Prayongrat

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Specific proton-beam configurations are needed to spare organs at risk (OARs), including lungs, heart, and spinal cord, when treating esophageal squamous cell carcinoma (ESCC) in the thoracic region. This study aimed to propose new intensity-modulated proton therapy (IMPT) beam configurations and to demonstrate the benefit of IMPT compared with intensity-modulated x-ray therapy (IMXT) for treating ESCC.

Material And Methods: IMPT plans with three different beam angle configurations were generated on CT datasets of 25 ESCC patients that were treated with IMXT. The IMPT beam designs were two commonly-used beam configurations (anteroposterior and posterior oblique) and a recently proposed beam configuration (anterosuperior with posteroinferior). The target doses were 50-54 Gy(RBE) and 60-64 Gy(RBE) to the low-risk and high-risk target volumes, respectively. Robust optimization was applied for the IMPT plans. The differences in the dose-volume parameters between the IMXT and IMPT plans were compared.

Results: With target coverage comparable to standard IMXT, IMPT had significantly lower mean doses to the OARs. IMPT with an anteroposterior opposing beam generated the lowest lung dose (mean = 7.1 Gy(RBE), V = 14.1%) and the anterosuperior with posteroinferior beam resulted in the lowest heart dose (mean = 12.8 Gy(RBE), V = 15.7%) and liver dose (mean = 3.9 Gy(RBE), V = 5.9%). For the subgroup of patients with an inferior tumor location (PTVs overlapping a part of the contoured heart), the novel beam demonstrated the optimal OARs sparing.

Conclusion: Compared with IMXT, the IMPT plans significantly reduced the radiation dose to the surrounding organs when treating ESCC. IMPT beam configuration selection depends on the tumor location relative to the heart.

Citing Articles

Efficacy and Safety in Proton Therapy and Photon Therapy for Patients With Esophageal Cancer: A Meta-Analysis.

Zhou P, Du Y, Zhang Y, Zhu M, Li T, Tian W JAMA Netw Open. 2023; 6(8):e2328136.

PMID: 37581887 PMC: 10427943. DOI: 10.1001/jamanetworkopen.2023.28136.

Achievements and challenges in normal tissue response modelling for proton therapy.

Engeseth G, Stokkevag C, Muren L Phys Imaging Radiat Oncol. 2022; 24:118-120.

PMID: 36405562 PMC: 9667307. DOI: 10.1016/j.phro.2022.11.004.

References

Shiraishi Y, Xu C, Yang J, Komaki R, Lin S . Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol. 2017; 125(1):48-54. DOI: 10.1016/j.radonc.2017.07.034. View

Langendijk J, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M . Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol. 2013; 107(3):267-73. DOI: 10.1016/j.radonc.2013.05.007. View

Ling T, Slater J, Nookala P, Mifflin R, Grove R, Ly A . Analysis of Intensity-Modulated Radiation Therapy (IMRT), Proton and 3D Conformal Radiotherapy (3D-CRT) for Reducing Perioperative Cardiopulmonary Complications in Esophageal Cancer Patients. Cancers (Basel). 2014; 6(4):2356-68. PMC: 4276971. DOI: 10.3390/cancers6042356. View

Zhang X, Zhao K, Guerrero T, McGuire S, Yaremko B, Komaki R . Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys. 2008; 72(1):278-87. PMC: 2610812. DOI: 10.1016/j.ijrobp.2008.05.014. View

Feng H, Sio T, Rule W, Bhangoo R, Lara P, Patrick C . Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy. J Appl Clin Med Phys. 2020; 21(11):141-152. PMC: 7700921. DOI: 10.1002/acm2.13049. View

Lin S, Merrell K, Shen J, Verma V, Correa A, Wang L . Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol. 2017; 123(3):376-381. DOI: 10.1016/j.radonc.2017.04.013. View

Prayongrat A, Xu C, Li H, Lin S . Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Adv Radiat Oncol. 2017; 2(3):301-307. PMC: 5605301. DOI: 10.1016/j.adro.2017.06.002. View

Celik E, Baus W, Baues C, Schroder W, Clivio A, Fogliata A . Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer. Radiat Oncol. 2020; 15(1):120. PMC: 7247143. DOI: 10.1186/s13014-020-01570-y. View

Shapiro J, van Lanschot J, Hulshof M, van Hagen P, van Berge Henegouwen M, Wijnhoven B . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015; 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. View

10.

Chen C, Li C, Chien C . Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol. 2016; 120(1):136-9. DOI: 10.1016/j.radonc.2016.04.042. View

11.

Shirato H, Le Q, Kobashi K, Prayongrat A, Takao S, Shimizu S . Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. J Radiat Res. 2018; 59(suppl_1):i2-i10. PMC: 5868193. DOI: 10.1093/jrr/rrx092. View

12.

Welsh J, Gomez D, Palmer M, Riley B, Mayankkumar A, Komaki R . Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011; 81(5):1336-42. PMC: 4086056. DOI: 10.1016/j.ijrobp.2010.07.2001. View

13.

Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V . High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thorac Cancer. 2017; 8(3):219-228. PMC: 5415457. DOI: 10.1111/1759-7714.12427. View

14.

Bhangoo R, DeWees T, Yu N, Ding J, Liu C, Golafshar M . Acute Toxicities and Short-Term Patient Outcomes After Intensity-Modulated Proton Beam Radiation Therapy or Intensity-Modulated Photon Radiation Therapy for Esophageal Carcinoma: A Mayo Clinic Experience. Adv Radiat Oncol. 2020; 5(5):871-879. PMC: 7557123. DOI: 10.1016/j.adro.2020.04.026. View

15.

Makishima H, Ishikawa H, Terunuma T, Hashimoto T, Yamanashi K, Sekiguchi T . Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res. 2015; 56(3):568-76. PMC: 4426925. DOI: 10.1093/jrr/rrv001. View

16.

Xi M, Xu C, Liao Z, Chang J, Gomez D, Jeter M . Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. Int J Radiat Oncol Biol Phys. 2017; 99(3):667-676. DOI: 10.1016/j.ijrobp.2017.06.2450. View

17.

Prayongrat A, Umegaki K, van der Schaaf A, Koong A, Lin S, Whitaker T . Present developments in reaching an international consensus for a model-based approach to particle beam therapy. J Radiat Res. 2018; 59(suppl_1):i72-i76. PMC: 5868183. DOI: 10.1093/jrr/rry008. View

18.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

19.

Thomas M, Defraene G, Levis M, Sterpin E, Lambrecht M, Ricardi U . A study to investigate the influence of cardiac motion on the robustness of pencil beam scanning proton plans in oesophageal cancer. Phys Imaging Radiat Oncol. 2021; 16:50-53. PMC: 7807867. DOI: 10.1016/j.phro.2020.09.003. View

20.

Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P . NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol. 2019; 141:33-40. DOI: 10.1016/j.radonc.2019.09.015. View